Comparative pathology of nerve sheath tumors in mouse models and humans

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Cancer Research (Impact Factor: 9.28). 06/2004; 64(10):3718-24. DOI: 10.1158/0008-5472.CAN-03-4079
Source: PubMed

ABSTRACT Despite the progress made in our understanding of the biology of neurofibromatosis (NF), the long-term clinical outcome for affected patients has not changed significantly in the past decades, and both NF1 and NF2 are still associated with a significant morbidity and a decreased life span. A number of NF1 and NF2 murine models have been generated to aid in the study of NF tumor biology and in the development of targeted therapies for NF patients. A single, universal pathological classification of the lesions generated in these murine models is essential for the validation of the models, for their analysis and comparison with other models, and for their future effective use in preclinical treatment trials. For the formulation of a pathological classification of these lesions, the WHO classification of human tumors was used as a reference. However, it was not adopted for the classification of the GEM lesions because of some important differences between the human and murine lesions. A novel classification scheme for peripheral nerve sheath tumors in murine models was therefore devised.

  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: The two types of neurofibromatosis are NF-1 and NF-2. Both cause abnormal cell growth in the central and peripheral nervous system. Each disease is inherited as an autosomal dominant trait, thus each child of an affected parent has a 50% chance of inheriting the disorder. Because there is no cure for either type of NF and treatment consists of amelioration of clinical symptoms, genetic counseling is the only preventive approach to this disease.
    Seminars in Oncology Nursing 12/1992; 8(4):265-71. DOI:10.1016/0749-2081(92)90039-6
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since 1988, the Tritium Remote Control and Monitoring System (TRECAMS) has performed crucial functions in support of D-T operations of the Tokamak Fusion Test Reactor (TFTR) at the Princeton Plasma Physics Laboratory (PPPL). Although plasma operations on TFTR were completed in 1997, the need for TRECAMS continued. During this period TRECAMS supported the TFTR tritium systems, the TFTR's shutdown and safing phase, and the TFTR Decontamination and Decommissioning (D&D) project. The most critical function of the TRECAMS in the post-TFTR era has been to provide a real-time indication of the airborne tritium levels in the tritium areas and the (HVAC) stacks. TRECAMS is a critical tool in conducting safe TFTR D&D tritium-line breaks and other tritium-related work activities.
    Fusion Engineering, 2002. 19th Symposium on; 02/2002
Show more